New Highly-Sensitive Ultra-Performance Liquid Chromatography - Mass Spectrometry Method for Quantification of Telmisartan in Human Plasma
Abstract
Purpose: To develop and validate a simple, rapid, sensitive and specific ultraperformance liquid chromatography mass spectrometry method for the quantification of the angiotensin II receptor antagonist, telmisartan (TEL), in human plasma.
Methods: After simple protein precipitation using acetonitrile and methanol, TEL and internal standard (IS) abiraterone were separated on Acquity UPLC BEHTM C18 column (50 x 2.1 mm, i.d. 1.7 μm, Waters, USA) using a mobile phase consisting of acetonitrile: 8 mM ammonium acetate containing 0.15 % formic acid (v/v) (70:30) pumped at a flow rate of 0.3 mL/min and detected by tandem mass spectrometry with positive ion mode. The ion transitions recorded in multiple reaction monitoring mode were m/z 515.27→276.13 for telmisartan and m/z 350.1 > 156.0 for internal standard, abiraterone.
Results: The assay exhibited a linear dynamic range of 1 – 200 ng/mL for telmisartan in human plasma with good correlation coefficient (0.995) and limit of quantitation of 1 ng/mL. The relative standard deviation for the intra- and inter-assay precision was between 0.75-11.50
Conclusion: The developed UPLC-MS/MS method is simple, rapid and highly sensitive, and should thus be suitable for pharmacokinetic and toxicokinetic studies in both animals and humans.
Keywords: Telmisartan, Ultra-Performance liquid chromatography, Tandem mass spectrometry, Pharmacokinetics, Toxicokinetics, High throughput analysis
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
